von Fliedner V
Schweiz Med Wochenschr. 1987 Feb 14;117(7):243-8.
Recent developments in biotechnology have resulted in a substantial renewal of cancer immunotherapy. In particular, the availability of murine monoclonal antibodies and recombinant biological response modifiers by genetic manipulation has made it possible to re-test abandoned concepts of adoptive humoral and cellular immunotherapy and to reconsider the biomodulation of the patient's immune system. Thus, the utilization of monoclonal antibodies to purge ex vivo autologous marrow from residual tumor cells has reached an advanced stage of clinical investigation in the field of autologous bone marrow transplantation for leukemia or lymphoma. Numerous promising clinical trials are being performed by the injection of monoclonal antibodies directed at tumor-associated antigens, coupled with cytotoxic agents (isotopes, drugs, toxins). In the area of recombinant technology, interferon-alpha has become the drug of choice for a particular form of chronic leukemia (hairy-cell leukemia). Interleukin-2 administered in conjunction with autologous activated lymphocytes has been shown to mediate significant anti-tumor activity in metastatic cancer patients. This review briefly describes recent clinical results obtained in cancer immunotherapy and discusses the potential of these new approaches.
生物技术的最新进展使得癌症免疫疗法有了实质性的复兴。特别是，通过基因操作获得鼠单克隆抗体和重组生物反应调节剂，使得重新测试被摒弃的过继性体液免疫疗法和细胞免疫疗法概念以及重新考虑患者免疫系统的生物调节成为可能。因此，利用单克隆抗体在体外清除自体骨髓中的残留肿瘤细胞，在白血病或淋巴瘤自体骨髓移植领域已进入临床研究的 advanced 阶段。通过注射针对肿瘤相关抗原的单克隆抗体并结合细胞毒性剂（同位素、药物、毒素），正在进行大量有前景的临床试验。在重组技术领域，干扰素-α已成为一种特定形式的慢性白血病（毛细胞白血病）的首选药物。与自体活化淋巴细胞联合使用的白细胞介素-2已被证明能在转移性癌症患者中介导显著的抗肿瘤活性。本综述简要描述了癌症免疫疗法最近取得的临床结果，并讨论了这些新方法的潜力。
